Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
616 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 87
- Run by
- Haitao Zhao, MD
See details and how to joinNCT07854600 - No phaseTaking peopleIndividualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
- Where
- Nanjing
- Age
- 18 years and over
- People
- 270
- Run by
- Nanjing Tianyinshan Hospital
See details and how to joinNCT06893887 - Phase 2Not yet taking people in ChinaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Changsha, Chengdu
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - Phase 2Taking peopleA Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 37
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06423170 - Early phase 1Not yet taking people in ChinaNK521 in the Treatment of Advanced Solid Tumors
- Where
- Hefei
- Age
- 18 years to 65 years
- People
- 18
- Run by
- Base Therapeutics (Shanghai) Co., Ltd.
See details and how to joinNCT07657416 - No phaseTaking peopleInstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years and over
- People
- 40
- Run by
- Beijing Municipal Administration of Hospitals
See details and how to joinNCT07848750 - No phaseTaking peopleA Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
- Where
- Guangdong
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Jie Yuan,MD
See details and how to joinNCT07850882 - Phase 2Not yet taking people in ChinaCryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 56
- Run by
- Fudan University
See details and how to joinNCT07846267 - Phase 3Taking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Kunming, Lishui, Luoyang, Nanchang, Nanning, Shandong, Shanghai, Shenyang, Weifang, Wuhan, Xi'an
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00 - Phase 3Taking peopleA Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
- Where
- Hefei
- Age
- 18 years and over
- People
- 590
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06618664 - Phase 2Taking peopleHAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou, Lanzhou, Zhengzhou
- Age
- 18 years and over
- People
- 76
- Run by
- Sun Yat-sen University
See details and how to joinNCT06737913 - Phase 2Taking peopleHAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Lianghe Lu
See details and how to joinNCT07841574 - No phaseTaking peopleMultimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
- Where
- Wuhan
- Age
- 18 years to 80 years
- People
- 400
- Run by
- Tongji Hospital
See details and how to joinNCT07838415 - No phaseTaking peopleBiomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
- Where
- Tianjin
- Age
- 18 years and over
- People
- 500
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07840092 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseNot yet taking people in ChinaTACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
- Where
- Nanjing
- Age
- 16 years and over
- People
- 596
- Run by
- Zhongda Hospital
See details and how to joinNCT07836309 - Phase 1Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Where
- Guangzhou, Shanghai
- Age
- 18 years and over
- People
- 232 worldwide
- Run by
- AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00 - Phase 2Taking peopleA Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Virogin Biotech Ltd.
See details and how to joinNCT07522476 - No phaseNot yet taking people in ChinaMultimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
- Where
- Aksu, Hangzhou, Jiaxing, Kaifeng, Nanchang, Taizhou
- Age
- 18 years to 80 years
- People
- 166
- Run by
- Zhejiang University
See details and how to joinNCT07596134 - Phase 2Taking peopleLenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 32
- Run by
- Shunda Du
See details and how to joinNCT07639138 - Phase 2Taking peopleOral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07793695 - Phase 2Not yet taking people in ChinaCryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
- Where
- Shanghai
- Age
- 18 years and over
- People
- 180
- Run by
- Fudan University
See details and how to joinNCT07829874 - No phaseTaking peopleMultimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
- Where
- Hefei
- Age
- 18 years to 80 years
- People
- 205
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07830576 - Phase 2Taking peopleSintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 54
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07831993 - Phase 2Taking peopleIrreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Shunda Du
See details and how to joinNCT07832006